ESMO 2019 and Late Breaking View overview page

2:30
ClarIDHy: updates and initial findings for ivosidenib in CCA
Ghassan Abou-Alfa • 28 Sep 2019
2:59
BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Véronique Dieras • 27 Sep 2019
1:34
OpACIN and OpACIN-neo trial updates
Christian Blank • 27 Sep 2019
3:46
CheckMate 459: updates on nivolumab monotherapy for HCC
Thomas Yau • 27 Sep 2019
2:57
Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma
Enrique Grande • 29 Sep 2019
9:59
PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPC
Maha Hussain
7:21
IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma
Enrique Grande
4:18
IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
David Spigel
4:20
KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC
Peter Schmid
4:34
Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results
Antonio González Martín • 29 Sep 2019
10:15
MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer
Dennis Slamon • 29 Sep 2019
9:02
Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC
Peter Schmid • 29 Sep 2019
5:12
MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer
George Sledge • 29 Sep 2019
2:14
FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
Arndt Vogel • 29 Sep 2019
2:52
OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
Georgina Long
9:49
PAOLA-1 Phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer
Isabelle Ray-Coquard • 28 Sep 2019
The content of VJOncology is intended for healthcare professionals